Robert E. Dempski - Dresher PA Edward C. Scholtz - King of Prussia PA Donald W. Nibbelink - Lansdale PA Scott A. Reines - New Hope PA
Assignee:
Merck & Co. - Rahway NJ
International Classification:
A61K 920 A61K 922 A61K 926
US Classification:
424469
Abstract:
A matrix or monolithic drug delivery system for the controlled release of carbidopa and levodopa consists of the two drugs uniformly dispersed in a polymer vehicle at a concentration that is greater than the solubility of either drug in the polymer. Treatment of parkinsonism with the controlled release formulation provides several advantages over treatment with the standard carbidopa/levidopa combinations presently employed.
Controlled Release Combination Of Carbidopa/Levodopa
Robert E. Dempski - Dresher PA Edward C. Scholtz - King of Prussia PA Donald W. Nibbelink - Lansdale PA Scott A. Reines - New Hope PA
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
A61K 922 A61K 926 A61K 3178
US Classification:
424469
Abstract:
A matrix or monolithic drug delivery system for the controlled release of carbidopa and levodopa consists of the two drugs uniformly dispersed in a polymer vehicle at a concentration that is greater than the solubility of either drug in the polymer. Treatment of parkinsonism with the controlled release formulation provides several advantages over treatment with the standard carbidopa/levodopa combination presently employed.
Controlled Release Combination Of Carbidopa/Levodopa
Robert E. Dempski - Dresher PA Edward C. Scholtz - King of Prussia PA Donald W. Nibbelink - Lansdale PA Scott A. Reines - New Hope PA
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
A61K 920 A61K 922 A61K 926
US Classification:
424469
Abstract:
A matrix or monolithic drug delivery system for the controlled release of carbidopa and levodopa consists of the two drugs uniformly dispersed in a polymer vehicle at a concentration that is greater than the solubility of either drug in the polymer. Treatment of parkinsonism with the controlled release formulation provides several advantages over treatment with the standard carbidopa/levodopa combinations presently employed.